Atomoxetine, ADHD, and the ongoing debate about increased risk of suicidal behaviors: the understudied role of kappa opioid receptor agonism Response to: Capuano A, Scavone C, Rafaniello C, et al. Atomoxetine in the treatment of attention deficit hyperactivity disorder and suicidal ideation. Expert Opin Drug Saf. 2014;13 Suppl 1:S69-78.
a Institute of Health and Environmental Research , Cleveland , OH , USA.
Keith
K
Fluegge
D018759:Adrenergic Uptake Inhibitors; D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000139:chemically induced*; D006801:Humans; D011437:Propylamines; D017473:Receptors, Opioid, kappa; D059020:Suicidal Ideation
D018759:Adrenergic Uptake Inhibitors; D011437:Propylamines; D017473:Receptors, Opioid, kappa; D000069445:Atomoxetine Hydrochloride